620
Views
5
CrossRef citations to date
0
Altmetric
Note

Anti-allergic effects of His-Ala-Gln tripeptide in vitro and in vivo

, , , &
Pages 380-383 | Received 13 Jul 2016, Accepted 26 Sep 2016, Published online: 12 Oct 2016

Figures & data

Fig. 1. Effects of HAQ peptide on the release of β-hexosaminidase (A), cell viability (B), and [Ca2+]i (C) of RBL-2H3 cells. (A) DNP-specific IgE-sensitized RBL-2H3 cells were challenged with DNP-HSA for 30 min. HAQ peptide was added at 10 min before antigen challenge. (B) Cell viability was measured using cell count reagent SF solution after various concentrations of HAQ peptide were added to anti-DNP IgE-sensitized RBL-2H3 cells followed by stimulation with DNP-HSA. (C) [Ca2+]i was measured by Calcium Kit-Fluo-3. Anti-DNP IgE-sensitized cells were incubated with Fluo-3 AM for 1 h and then incubated with 500 μM HAQ peptide or PBS for 10 min. Then, the treated cells were stimulated with DNP-HSA, and the fluorescence intensity was measured. (○), non-HAQ peptide-treated cells not sensitized with anti-DNP IgE; (▲), HAQ peptide-treated cells stimulated with antigen; (●), non-HAQ peptide treated cells stimulated with antigen.

Note: Data are presented as the mean ± SD (n = 5). *p < 0.05 between each group.
Fig. 1. Effects of HAQ peptide on the release of β-hexosaminidase (A), cell viability (B), and [Ca2+]i (C) of RBL-2H3 cells. (A) DNP-specific IgE-sensitized RBL-2H3 cells were challenged with DNP-HSA for 30 min. HAQ peptide was added at 10 min before antigen challenge. (B) Cell viability was measured using cell count reagent SF solution after various concentrations of HAQ peptide were added to anti-DNP IgE-sensitized RBL-2H3 cells followed by stimulation with DNP-HSA. (C) [Ca2+]i was measured by Calcium Kit-Fluo-3. Anti-DNP IgE-sensitized cells were incubated with Fluo-3 AM for 1 h and then incubated with 500 μM HAQ peptide or PBS for 10 min. Then, the treated cells were stimulated with DNP-HSA, and the fluorescence intensity was measured. (○), non-HAQ peptide-treated cells not sensitized with anti-DNP IgE; (▲), HAQ peptide-treated cells stimulated with antigen; (●), non-HAQ peptide treated cells stimulated with antigen.

Fig. 2. LHE-specific IgE (A) and IgG1 (B) levels in sera of control and HAQ peptide-fed C3H/HeJ mice. □, unsensitized, PBS orally administered group (n = 5); ■, LHE-sensitized, PBS orally administered group (n = 9);

, LHE-sensitized, HAQ orally administered group (n = 8).

Notes: Data are expressed as the mean ± SEM. *p < 0.05. Groups of mice that had received orally administered HAQ peptide or PBS during sensitization to OVA or PBS were challenged intraperitoneally. Unsensitized animals received the vehicle alone. Blood was obtained from the orbital veins of mice at 11 days after injection and subjected to ELISAs specific for IgE or IgG1 against LHE.
Fig. 2. LHE-specific IgE (A) and IgG1 (B) levels in sera of control and HAQ peptide-fed C3H/HeJ mice. □, unsensitized, PBS orally administered group (n = 5); ■, LHE-sensitized, PBS orally administered group (n = 9); Display full size, LHE-sensitized, HAQ orally administered group (n = 8).

Fig. 3. Allergic symptoms after oral challenge in mice presensitized in the presence of HAQ peptide. ○, unsensitized, PBS orally administered group (n = 5); ●, LHE-sensitized, PBS orally administered group (n = 9);

, LHE-sensitized, HAQ orally administered group (n = 8).

Notes: Data are expressed as the mean ± SEM. *p < 0.05 between each group. Groups of mice that had received orally administered HAQ peptide or PBS during sensitization to LHE or PBS were challenged intraperitoneally. (A) Symptom scores of systemic anaphylaxis. Anaphylaxis-like symptoms were scored at 20 min after oral challenge on a scale from 0 (no symptoms) to 5 (death) as described in the Materials and Methods. (B) Rectal temperature. The rectal temperature was measured at 30 min after oral challenge.
Fig. 3. Allergic symptoms after oral challenge in mice presensitized in the presence of HAQ peptide. ○, unsensitized, PBS orally administered group (n = 5); ●, LHE-sensitized, PBS orally administered group (n = 9); Display full size, LHE-sensitized, HAQ orally administered group (n = 8).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.